Uterine fibroids cost European SMEs 3.45 million working days per annum. The Wider Societal and Policy Objectives of Our Project - are to benefit European society by improving embolotherapy for fibroids using drug-eluting beads and reducing: the length of fibroid treatment by 90 %; the number of women having hysterectomies by 5%; the pain experienced by women by 50%; and the post-operative infection rate by 50%.
In addition, the relatively low cost of the POS-BEADD technology will enable the increasing use of embolization treatments in all European countries including the Candidate Countries and this will support the policies of the European Union to bring the health of Eastern Europeans up to the same standard as those of the 15 states To achieve this our Technical Targets are to discover technological routes to enable the development of the following: positively charged beads made from PVA; that are lyophilized and carrying drugs at concentrations between 20 and 100 mg/ml of beads;
Call for proposal
See other projects for this call